共 50 条
- [41] Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy developmentCANCER, 2016, 122 (22) : 3456 - 3463Lampson, Benjamin L.Nishino, MizukiDahlberg, Suzanne E.Paul, DanieSantos, Abigail A.Jaenne, Pasi A.Oxnard, Geoffrey R.
- [42] Acquired Resistance to EGFR Tyrosine Kinase Inhibitors is Associated With Low Efficacy of Radiation Therapy for Brain Metastases From EGFR-mutant Lung AdenocarcinomaINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S102 - S102Hirata, H.Nakamura, K.Kunitake, N.Shioyama, Y.Sasaki, T.Nonoshita, T.Inoue, K.Nagashima, A.Ono, M.Honda, H.
- [43] Local therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Yu, Helena AlexandraSima, Camelia S.Drilon, Alexander Edward Dela CruzVarghese, Anna M.Pietanza, Maria CatherineAzzoli, Christopher G.Rizvi, Naiyer A.Krug, Lee M.Kris, Mark G.Miller, Vincent A.Riely, Gregory J.
- [44] Immune microenvironment change after acquiring resistance to EGFR TKI therapy in EGFR mutant non-small cell lung cancerMOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)Kim, Tae-JungKang, Jin-HyoungHong, Sook-hee
- [45] AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung CancerCANCER DISCOVERY, 2022, 12 (11) : 2666 - 2683Noronha, AshishNataraj, Nishanth BelugaliLee, Joo SangZhitomirsky, BennyOren, YaaraOster, SaraLindzen, MoshitMukherjee, SaptaparnaWill, RainerGhosh, SomaSimoni-Nieves, ArturoVerma, AakankshaChatterjee, RishitaBorgoni, SimoneRobinson, WellesSinha, SanjuBrandis, AlexanderKerr, D. LucasWu, WeiSekar, ArunachalamGiri, SuvenduChung, YoungminDrago-Garcia, DianaDanysh, Brian P.Lauriola, MattiaFiorentino, MichelangeloArdizzoni, AndreaOren, MosheBlakely, Collin M.Ezike, JideoforWiemann, StefanParida, LaxmiBivona, Trever G.Aqeilan, Rami, IBrugge, Joan S.Regev, AvivGetz, GadRuppin, EytanYarden, Yosef
- [46] Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIsLUNG CANCER, 2017, 113 : 106 - 114Lee, Choong-kunKim, SoraLee, Jae SeokLee, Jeong EunKim, Sung-mooYang, In SeokKim, Hye RyunLee, Jeong HoKim, SangwooCho, Byoung Chul
- [47] Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase InhibitorsJOURNAL OF THORACIC ONCOLOGY, 2013, 8 (03) : 346 - 351Yu, Helena A.Sima, Camelia S.Huang, JamesSolomon, Stephen B.Rimner, AndreasPaik, PaulPietanza, M. CatherineAzzoli, Christopher G.Rizvi, Naiyer A.Krug, Lee M.Miller, Vincent A.Kris, Mark G.Riely, Gregory J.
- [48] Overexpression of Reactive Oxygen Species Modulator 1 Predicts Unfavorable Clinical Outcome in EGFR-Mutant Lung Adenocarcinomas Treated With Targeted TherapyFRONTIERS IN ONCOLOGY, 2021, 11Kwack, Won GunSung, Ji-YounLee, Seung Hyeun
- [49] Pulse-continuous dose erlotinib as initial targeted therapy for patients with EGFR-mutant lung cancers with untreated brain metastases.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Kris, Mark G.Arbour, Kathryn CeciliaRiely, Gregory J.Ni, AiBeal, KathrynDaras, MarizaHayes, Sara A.Young, Robert J.Rodriguez, Christopher R.Pao, WilliamYu, Helena Alexandra
- [50] Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapyMedical Oncology, 2017, 34Akimasa SekineHiroaki Satoh